EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer

Randomisierte klinische Studie zu beschleunigter präoperativer hyperfraktionierter Radiotherapie versus präoperativer hyperfraktionierter Radio-Chemotherapie bei lokal fortgeschrittenem Rektumkarzinom

Adam Idasiak iD, Barbara Ziółkowska, Marcin Rajczykowski, Katarzyna Galwas, Iwona Dębosz-Suwińska, Marcin Zeman, Jolanta Mrochem-Kwarciak, Rafał Suwiński

British Journal of Radiology · 01.11.2024 · 97 (1163) · 1879-1889

DOI: 10.1093/bjr/tqae176 ↗

Auf einen Blick

Bei resektablem Rektumkarzinom war die pathologische Komplettremission unter HART-CT häufiger als unter HART. Unterschiede bei OS und DFS waren nicht signifikant.

Fragestellung

Vergleich der pathologischen Ansprechraten nach präoperativer hyperfraktionierter Radiotherapie mit 5FU-Chemotherapie (HART-CT) versus HART bei resektablem Rektumkarzinom.

Methode

Randomisierte klinische Studie bei Patient:innen mit T2/N+ oder T3/any N; HART zweimal täglich mit 28 Fraktionen à 1.5 Gy bis 42 Gy oder HART-CT; medianes Follow-up 5.6 Jahre.

Ergebnisse

187 Patient:innen auswertbar: 95 HART, 92 HART-CT. Komplettremission: 4/95, 4 % vs. 11/92, 12 % (P = .045). OS: P = .13, HR 0.82 (95 %-KI 0.63-1.06); DFS: P = .32, HR 0.88 (95 %-KI 0.69-1.13).

Schlussfolgerung der Autor:innen

Die hyperfraktionierte präoperative Radiotherapie mit gleichzeitiger 5-Fu-basierter Chemotherapie verbesserte die pathologische Ansprechrate gegenüber HART. Die günstigeren OS- und DFS-Werte erreichten keine Signifikanz.

Kernaussagen

  • Komplettremission: 4/95 unter HART vs. 11/92 unter HART-CT
  • OS und DFS unterschieden sich nicht signifikant
  • Spätkomplikationen waren in beiden Gruppen ähnlich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Radiology, online erschienen am 06.09.2024. Verfasst von Adam Idasiak und 7 weiteren Autor:innen. Beteiligte Einrichtung: IInd Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Pola…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Dose Fractionation, Radiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this study was to compare pathological response rates after preoperative hyperfractionated radiotherapy with co-administration of chemotherapy based on 5FU (HART-CT) versus preoperative hyperfractionated radiotherapy (HART) in patients with resectable rectal cancer.

Methods

Patients with T2/N+ or T3/any N rectal cancer were randomized either to HART twice a day (28 fractions of 1.5 Gy) to total dose 42 Gy or to HART-CT. Tumour regression grade was postoperatively assessed according to the 4-point scale as recommended by the American Joint Committee on Cancer (AJCC). The secondary endpoints included overall survival (OS), disease-free survival (DFS), toxicity of preoperative treatment, locoregional, and distant failure rates. There were 187 patients eligible for analysis: 95 in HART and 92 in the HART-CT. Median follow-up was 5.6 years.

Results

The analysis demonstrated a significantly higher chance of achieving pathologic complete response in HART-CT arm: complete response was achieved in 4/95, 4% (HART) and 11/92, 12% (HART-CT) (P = .045). The differences in OS and DFS, while tending to favour HART-CT, were not significant: OS (P = .13, hazard ratio [HR] = 0.82, 95% CI, 0.63-1.06) and DFS (P = .32; HR = 0.88, 95% CI, 0.69-1.13). The locoregional failure and distant metastases rates did not statistically differ between the trial arms. The rate of late complications was similar (P = .51), grade 3+ being 8% versus 11% in the HART/HART-CT group, respectively.

Conclusions

The hyperfractionated preoperative radiotherapy with concurrent 5-Fu-based chemotherapy (HART-CT) improved pathological response rate compared to HART. This translated into favourable OS and DFS in HART-CT, but the differences did not reach the threshold for significance. Advances in knowledge A new hyperfractionated chemo-RT scheme is proposed. Histopathological major response (TRG 0-1) is associated with better clinical outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsDose Fractionation, RadiationHumansMaleFemaleMiddle AgedAgedFluorouracilAdultChemoradiotherapyTreatment OutcomePreoperative CareDisease-Free SurvivalAntimetabolites, Antineoplastic

Stichwörter der Autor:innen

TRGhistopathological responsehyperfractionated radiotherapyrectal cancer

Substanzen

FluorouracilAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • IInd Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
  • Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
  • The Oncologic and Reconstructive Surgery Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.
  • Analytics and Clinical Biochemistry Department, Maria Sklodowska-Curie National Research Institute of Oncology, 44-100 Gliwice, Poland.

ORCID-Profile: Adam Idasiak

Zitieren

APA

Idasiak, A., Ziółkowska, B., Rajczykowski, M., Galwas, K., Dębosz-Suwińska, I., Zeman, M., Mrochem-Kwarciak, J., & Suwiński, R. (2024). Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer. British Journal of Radiology, 97(1163), 1879-1889. https://doi.org/10.1093/bjr/tqae176

Vancouver

Idasiak A, Ziółkowska B, Rajczykowski M, Galwas K, Dębosz-Suwińska I, Zeman M, et al. Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer. British Journal of Radiology. 2024;97(1163):1879-1889. doi:10.1093/bjr/tqae176

BibTeX
@article{Idasiak2024,
  author = {Idasiak, Adam and Ziółkowska, Barbara and Rajczykowski, Marcin and Galwas, Katarzyna and Dębosz-Suwińska, Iwona and Zeman, Marcin and Mrochem-Kwarciak, Jolanta and Suwiński, Rafał},
  title = {Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer},
  journal = {British Journal of Radiology},
  year = {2024},
  volume = {97},
  number = {1163},
  pages = {1879--1889},
  doi = {10.1093/bjr/tqae176}
}
Kostenlos starten →